These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32126256)

  • 1. Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.
    Prior H; Baldrick P; Beken S; Booler H; Bower N; Brooker P; Brown P; Burlinson B; Burns-Naas LA; Casey W; Chapman M; Clarke D; de Haan L; Doehr O; Downes N; Flaherty M; Gellatly N; Moesgaard SG; Harris J; Holbrook M; Hui J; Jones D; Jones K; Kedar H; Mahl A; Manninen A; McGuire A; Mortimer-Cassen E; Peraza M; Pugsley MK; Richard J; Roberts R; Roosen W; Rothfuss A; Schoenmakers A; Sewell F; Weaver R; Weir L; Wolfreys A; Kimber I
    Regul Toxicol Pharmacol; 2020 Jun; 113():104624. PubMed ID: 32126256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
    Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
    Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Definition of "Similar Toxicities": Case Studies Illustrating Industry and Regulatory Interpretation of ICH S6(R1) for Long-Term Toxicity Studies in One or Two Species.
    Prior H; Clarke DO; Jones D; Salicru E; Schutten MM; Sewell F
    Int J Toxicol; 2022; 41(3):171-181. PubMed ID: 35435047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.
    Sewell F; Chapman K; Baldrick P; Brewster D; Broadmeadow A; Brown P; Burns-Naas LA; Clarke J; Constan A; Couch J; Czupalla O; Danks A; DeGeorge J; de Haan L; Hettinger K; Hill M; Festag M; Jacobs A; Jacobson-Kram D; Kopytek S; Lorenz H; Moesgaard SG; Moore E; Pasanen M; Perry R; Ragan I; Robinson S; Schmitt PM; Short B; Lima BS; Smith D; Sparrow S; van Bekkum Y; Jones D
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):413-29. PubMed ID: 25078890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of Consortia Recommendations for Justification of Animal Use Within Current and Future Drug Development Paradigms.
    Prior H; Monticello T; Boulifard V; Brennan FR; Kimber I
    Int J Toxicol; 2019; 38(4):319-325. PubMed ID: 31220983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
    Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B
    Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Justification for species selection for pharmaceutical toxicity studies.
    Prior H; Haworth R; Labram B; Roberts R; Wolfreys A; Sewell F
    Toxicol Res (Camb); 2020 Dec; 9(6):758-770. PubMed ID: 33442468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain.
    Prior H; Andrews L; Cauvin A; Chien H; Clarke DO; Datta K; Dempster M; Dybdal N; Freebern W; de Haan L; Herzyk D; Hey A; Kissner T; Kronenberg S; Leach MW; Lee D; Reid K; Schutte K; Sewell F; Trouba K; Ulrich P; van Aerts L; van Meer P; Weir L
    Regul Toxicol Pharmacol; 2023 Feb; 138():105339. PubMed ID: 36649820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.
    Colleton C; Brewster D; Chester A; Clarke DO; Heining P; Olaharski A; Graziano M
    Toxicol Pathol; 2016 Apr; 44(3):458-66. PubMed ID: 27006130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dog as a Second Species for Toxicology Testing Provides Value to Drug Development.
    Bower N; Achanzar WE; Boulifard V; Brinck PR; Kittel B; Vahle JL
    Int J Toxicol; 2022 Dec; 41(6):431-441. PubMed ID: 36112859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
    de Zafra CLZ; Sasseville VG; Matsumoto S; Freichel C; Milton M; MacLachlan TK; Farman C; Raymond I; Gupta S; Newton R; Atzpodien EA; Thackaberry EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():221-230. PubMed ID: 28322894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development and nonclinical to clinical translational databases: past and current efforts.
    Monticello TM
    Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.